Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

An elderly woman sits with a doctor, both wear masks alzheimer disease agitation
Conference Coverage
AXS-05 Shows Efficacy and Safety in Agitation in Alzheimer Disease
03/19/2026
Brionna Mendoza
New data presented in a poster at the 2026 Psych Congress NP Institute in Nashville, TN, highlight the efficacy and safety of AXS-05 (dextromethorphan-bupropion) based on results from the Phase 2/3 ADVANCE-1 and Phase 3 ACCORD-1 randomized...
New data presented in a poster at the 2026 Psych Congress NP Institute in Nashville, TN, highlight the efficacy and safety of AXS-05 (dextromethorphan-bupropion) based on results from the Phase 2/3 ADVANCE-1 and Phase 3 ACCORD-1 randomized...
New data presented in a poster...
03/19/2026
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
From Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
person holding cannabis
Cannabis Use Requiring Acute Care Increases Dementia Risk
04/22/2025
Jolynn Tumolo
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older...
04/22/2025
Neurology
From Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
From Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network

News

A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
spilled bottle of white pills
News
Clozapine Shows Superior Response After First Antipsychotic Failure
03/20/2026
Maria Mantas
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic, according to recent...
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic, according to recent...
Clozapine was more effective...
03/20/2026
Psych Congress Network
a person holds a glass of water and pills
News
Antidepressant Use Patterns May Help Personalize MDD Treatment
03/16/2026
Brionna Mendoza
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in...
03/16/2026
Psych Congress Network
a man running on a beach
News
Review Urges Greater Exercise Integration in Schizophrenia, SMI Care
03/16/2026
Brionna Mendoza
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
The integration of physical...
03/16/2026
Psych Congress Network
a man sits alone by a lake
News
Loneliness Partially Mediates Link Between Anxiety, Depression, and Suicidal Ideation
03/12/2026
Maria Mantas
Loneliness significantly contributes to the relationship between anxiety symptoms, depressive symptoms, and suicidal ideation among US adults, according to recent analysis findings.
Loneliness significantly contributes to the relationship between anxiety symptoms, depressive symptoms, and suicidal ideation among US adults, according to recent analysis findings.
Loneliness significantly...
03/12/2026
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Migraine Nearly Doubles Depression and Anxiety Risk in Cohort Study
03/10/2026
Brionna Mendoza
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2...
03/10/2026
Psych Congress Network
orange pill bottle antidepressant depression major depressive disorder MDD
News
Decision Tool Reduces Antidepressant Dropout in Major Depressive Disorder
03/06/2026
Brionna Mendoza
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support...
03/06/2026
Psych Congress Network
a strand of DNA
News
Copy Number Variant Deletions Linked to Earlier Schizophrenia Onset
03/05/2026
Maria Mantas
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
Increased copy number variant...
03/05/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
News
Indirect Costs Drive $366B Schizophrenia Burden in US
02/27/2026
Brionna Mendoza
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic...
02/27/2026
Psych Congress Network
Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
psilocybin-containing mushrooms in a beaker
News
Synthetic Psilocybin Meets Primary Endpoint in Phase 3 Treatment-Resistant Depression Trial
02/19/2026
Maria Mantas
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin...
02/19/2026
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Intervention in Bulimia Nervosa
02/26/2026
Maria Mantas
Do you remember what the APA guideline recommends? Test your knowledge with this quiz!
Do you remember what the APA guideline recommends? Test your knowledge with this quiz!
Do you remember what the APA...
02/26/2026
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Screen Time, Brain Structure, and ADHD in Children
02/12/2026
Maria Mantas
Do you remember what the research says? Test your knowledge with this quick quiz!
Do you remember what the research says? Test your knowledge with this quick quiz!
Do you remember what the...
02/12/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Quiz
Intranasal Esketamine Dosage for Adult MDD
02/04/2026
Brionna Mendoza
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and administration knowledge with this quiz!
Test your prescribing and...
02/04/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Brain Aging in Schizophrenia
01/22/2026
Maria Mantas
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent research with this quick quiz!
Test your knowledge of recent...
01/22/2026
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet
Guidelines Quiz
Medication Monitoring in Patients With BPD
01/20/2026
Brionna Mendoza
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA guidelines with this quiz!
Test your knowledge of APA...
01/20/2026
Psych Congress Network
Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
Joseph Goldberg, MD
Quiz
Diagnosing Mixed Features in Bipolar Disorder
12/03/2025
Joseph F. Goldberg, MD
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Depression, Inflammation, and Insomnia
11/19/2025
Brionna Mendoza
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
11/19/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network

Perspectives

marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
Leslie Citrome, MD
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Paul Schulz, MD
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
Marc E. Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Marc E. Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Brittany Albright MD, MPH
Videos
Taking a Patient-Centered Approach to Deprescribing in Psychiatry
03/13/2026
Brittany Albright, MD, MPH
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
In this insightful discussion,...
03/13/2026
Psych Congress Network
Chelsie Monroe, APN, PMHNP-BC
Videos
Is It Fatigue or Sleepiness? Identifying Narcolepsy in Practice
03/09/2026
Chelsie Monroe, PMHNP-BC, APN
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC,...
03/09/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Videos
Practical Guidance for Ethical AI Use in Psychiatry
03/06/2026
Desiree Matthews, PHMNP-BC
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
In this video, Desiree Matthews,...
03/06/2026
Psych Congress Network
Saundra Jain, MA, PsyD, LPC
Videos
Integrating Digital Therapeutics Into GAD Care
02/20/2026
Saundra Jain, MA, PsyD, LPC
Saundra Jain, MA, PsyD, LPC, discusses how clinicians can leverage digital therapeutics for the treatment of generalized anxiety disorder (GAD).
Saundra Jain, MA, PsyD, LPC, discusses how clinicians can leverage digital therapeutics for the treatment of generalized anxiety disorder (GAD).
Saundra Jain, MA, PsyD, LPC,...
02/20/2026
Psych Congress Network
Edward Kaftarian, MD
Videos
Maintaining HIPAA Compliance and Protecting Patient Data via Telehealth
02/09/2026
Edward Kaftarian, MD
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Edward Kaftarian, MD, Steering...
02/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
Michael Asbach, DMsc, PA-C
Videos
Differentiating Bipolar II Disorder From Other Psychiatric Conditions
12/08/2025
Michael Asbach, DMSc, PA-C
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach,...
12/08/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC
Videos
Using Digital Tools to Reduce Clinician Burnout
12/03/2025
Desiree Matthews, PHMNP-BC
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych...
12/03/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use